David A. Siegel Oyster Point Pharma, Inc. Transaction History

Two Sigma Advisers, LP

  • $41.3 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2020

Feb 16, 2021
SELL
$18.13 - $25.18 $262,885 - $365,110
-14,500 Closed
0 $0
Q3 2020

Nov 16, 2020
SELL
$17.83 - $29.12 $99,847 - $163,072
-5,600 Reduced 27.86%
14,500 $306,000
Q2 2020

Aug 14, 2020
BUY
$27.86 - $35.93 $395,612 - $510,206
14,200 Added 240.68%
20,100 $580,000
Q1 2020

May 15, 2020
BUY
$23.65 - $40.96 $139,535 - $241,664
5,900 New
5,900 $207,000

About Oyster Point Pharma, Inc.

OYST Quotes by TradingView
  • Ticker OYST
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,831,500
  • Description
  • Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry ...
More about OYST
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email